Summary
Sixty nine patients with Parkinson's disease were treated with L-DOPA for more than a year. L-DOPA produced remarkable improvement in akinetic patients, moderate improvement in rigidity and slight improvement in tremor. The degree of improvement in akinesia, rigidity and tremor tended to be reversely related to the severity of the disease. Rigidity and akinesia improved better in young patients, but there was no correlation between age and the response of tremor to the treatment. Except for rigidity there was no correlation between the improvement and the duration of the disease.
Zusammenfassung
69 Parkinsonpatienten wurden während mehr als 1 Jahr mit L-DOPA behandelt. Es wurde dadurch bei akinetischen Patienten eine beachtliche, bei Patienten mit Rigor eine mäßige und bei Patienten mit Tremor eine geringfügige Besserung erreicht. Das Ausmaß der Besserung war in allen drei Formen um so geringer, je ausgeprägter die Symptome bei Behandlungsbeginn waren. Rigor und Akinesie sprachen bei jungen Patienten besser auf die Therapie an, aber es bestand keine Korrelation zwischen dem Alter der Patienten und der Beeinflußbarkeit des Tremors durch die L-DOPA-Therapie. Außer für den Rigor bestand keine Korrelation zwischen dem Ausmaß der Besserung und der Dauer der Erkrankung vor Behandlungsbeginn.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abramsky, O., Lavy, S., Carmon, A.: A test of objective evaluation for motor performance in patients receiving L-DOPA for Parkinson's disease. J. neurol. Sci. 12, 105–108 (1971).
Barbeau, A.: L-DOPA therapy in Parkinson's disease. Critical review of nine years experience. Canad. med. Ass. J. 101, 791–800 (1969).
Birkmayer, W., Hornykiewicz, O.: Der 3–4 dioxyphenylalanin (DOPA) effect bei der Parkinsonakinase. Wien. klin. Wschr. 73, 783–788 (1961).
Calne, D. B., Spiers, A. S. D., Stern, G. M., Laurence, D. R.: L-DOPA in idiopathic parkinsonism. Lancet 1969 II, 973–976.
Cotzias, G. C.: Levodopa in the treatment of parkinsonism. J. Amer. med. Ass. 218, 1903–1908 (1971).
Cotzias, G. C., Papavasilliou, P. S., Gellene, R.: Modification of parkinsonism: chronic treatment with L-DOPA. New Engl. J. Med. 280, 337–345 (1969).
Editorial: Evaluation of levodopa for parkinsonism. J. Amer. med. Ass. 215, 1969–1972 (1971).
Godwin-Austen, R. B., Kantamanen, B. D., Curson, G.: Comparison of benefit from L-DOPA in parkinsonism with increase of amine metabolites in the CSF. J. Neurol. Neurosurg. Psychiat. 34, 219–223 (1971).
Godwin-Austen, R. B., Tomlinson, E. B., Frears, C. C., Kok, H. W. L.: Effects of L-DOPA in Parkinson's disease. Lancet 1969 II, 165–168.
Lavy, S., Carmon, A., Abramsky, O., Feldman, S.: Evaluation of the therapeutic effects of l-Dopa in Parkinson's disease. Harefuah 79, 547–549 (1970).
Mawdsley, C.: Treatment of Parkinsonism with levodopa. Brit. med. J. 1970 I, 331–337.
McDowell, F., Lee, J. E., Swift, T., Sweet, R. D., Ogsburg, J. S., Dessler, J. T.: Treatment of Parkinson's syndrome with l-dihydroxyphenylalanine (levodopa). Ann. intern. Med. 72, 29–35 (1970).
Peaston, M. J. T., Bianchine, J. R.: Metabolic studies and clinical observations during L-DOPA treatment of Parkinson's disease. Brit. med. J. 1970 I, 400–403.
Rinne, U. K., Sonninen, V., Siirtola, T.: L-DOPA treatment in Parkinson's disease. Europ. Neurol. 4, 348–369 (1970).
Sachs, O. W., Messeloff, C. R., Schwartz, W. F.: Long term effects of levodopa in severity disabled patients. J. Amer. med. Ass. 213, 2270 (1970).
Yahr, M. D., Duvoisin, R. C., Schear, M. J., Barrett, R. E., Howhn, M. M.: Treatment of parkinsonism with levodopa. Arch. Neurol. (Paris) 21, 343–354 (1969).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lavy, S., Abramsky, O., Carmon, A. et al. Certain predictions on the effectiveness of l-DOPA on parkinsonism. Z. Neurol. 203, 271–278 (1973). https://doi.org/10.1007/BF00316184
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00316184